EPEero Poukka

Eero Poukka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eero Poukka has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Tuija Leino

    Department of Public Health, Finnish Institute for Health and Welfare, Helsinki, Finland

    11 shared publications
  • Ulrike Baum

    Department of Public Health, Finnish Institute for Health and Welfare, Helsinki, Finland

    9 shared publications
  • Emilia Myrup Thiesson

    Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark

    7 shared publications
  • Nicklas Pihlström

    Division of Use and Information, Swedish Medical Products Agency, Uppsala, Sweden

    6 shared publications
  • Rickard Ljung

    Division of Use and Information, Swedish Medical Products Agency, Uppsala, Sweden

    6 shared publications
  • Ulrike Baum

    Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare

    6 shared publications

Latest Publications

  • Open Access

    Brand-specific influenza vaccine effectiveness in three Nordic countries during the 2024–2025 season: a target trial emulation study based on registry data

    by Kristyna Faksova, Emilia Myrup Thiesson, Nicklas Pihlström, Ulrike Baum, Tor Biering-Sørensen, Eero Poukka, Tuija Leino, Rickard Ljung, Anders Hviid


  • Open Access

    Influenza Epidemiology in Finland During and After the COVID‐19 Pandemic: Surveillance Data Analysis (2019–2024)

    by Ulrike Baum, Niina Ikonen, Oskari Luomala, Eero Poukka, Tuija Leino, Hanna Nohynek

    Background: The Finnish influenza surveillance system combines traditional virological surveillance and analyses of electronic health records. This paper describes the influenza epidemiology in Finland (population: 5.5 million) during and after the COVID‐19 pandemic based on national surveillance data from 2019 to 2024.Methods: Influenza incidence was evaluated based on three register‐based outcomes: laboratory‐confirmed infections, primary health care visits, and hospitalizations. Virus‐type distributions were analyzed from respiratory specimens. In register‐based analyses, vaccination coverage and vaccine effectiveness were assessed for the two cohorts universally included in the Finnish vaccination program: children aged ≤ 6 years and adults aged ≥ 65 years.Results: The 2019/2020 influenza epidemic ended with the introduction of COVID‐19 containment measures. In 2020/2021, influenza was largely absent. The 2021/2022 epidemic peaked exceptionally late. Influenza activity returned to prepandemic levels in 2022/2023. None of the 717 sentinel specimens tested positive for B/Yamagata. Although the percentage of vaccinated young children was constant (31% [100,387/323,614] to 37% [126,984/346,344]), the percentage of vaccinated elderly people increased from 48% (577,404/1,211,732) in 2019/2020 to 63% (787,771/1,255,644) in 2021/2022. The vaccine effectiveness against hospitalization due to laboratory‐confirmed influenza in young children and elderly people was 68% (95% confidence interval: 38%; 83%) and 42% (34%; 50%) in 2022/2023, respectively, and slightly lower in 2023/2024.Conclusions: The COVID‐19 pandemic had two potentially lasting effects on influenza: elimination of the B/Yamagata lineage and improved vaccination coverage in the elderly population in Finland. To strengthen the Finnish influenza surveillance system, participation in sentinel surveillance must be improved.


  • Bias in control selection associated with the use of rapid tests in influenza vaccine effectiveness studies

    by Eero Poukka, Caitriona Murphy, Loretta Mak, Samuel M S Cheng, Malik Peiris, Tim K Tsang, Sheena G Sullivan, Benjamin J Cowling

    Background: In test-negative design (TND) studies that use rapid tests to estimate influenza vaccine effectiveness (VE), a common concern is case–control misclassification due to imperfect diagnostic accuracy. An imperfect test can also fail to exclude from the control group people infected with other influenza types or other vaccine-preventable respiratory viruses. We investigated these biases while evaluating VE for the 2023/24 seasonal influenza vaccination. Methods: A TND study was conducted among outpatients aged ≥6 months of age who visited an outpatient clinic in Hong Kong between 15 December 2023 and 13 August 2024. VE was estimated for polymerase chain reaction (PCR)- and rapid-test-confirmed influenza A and B with exclusions of other types of influenza and SARS-CoV-2 based on either PCR or rapid test. Alternatively, for the exclusion of SARS-CoV-2, we adjusted the analysis with COVID-19 vaccination. VE was estimated by using logistic regression adjusted for confounders. Results: In a study population of 1691 participants, VE against influenza A by PCR was 49% [95% confidence interval (CI) 26%–65%] after the exclusion of PCR-confirmed influenza B and SARS-CoV-2 controls. The corresponding VE against influenza B was 65% (95% CI 35%–81%). VE estimated by adjusting for COVID-19 vaccination status yielded similar estimates to these. When case–control status and exclusions from test-negative controls were determined by using the rapid test, VE was reduced by 5%age–15%age points. Conclusion: In TND studies using rapid tests, reduced sensitivity affects both case–control classification and control group exclusions, potentially causing bias. New methods for these biases could help to adapt participatory cohorts for the monitoring of VE for influenza, COVID-19, and respiratory syncytial virus.


  • Open Access

    Bias in control selection associated with the use of rapid tests in influenza vaccine effectiveness studies

    by Eero Poukka, Caitriona Murphy, Loretta Mak, Samuel M. S. Cheng, Malik Peiris, Tim K. Tsang, Sheena G. Sullivan, Benjamin J. Cowling

    In test-negative design studies that use rapid tests to estimate influenza vaccine effectiveness (VE) a common concern is case/control misclassification due to imperfect test sensitivity and specificity. However, an imperfect test can also fail to exclude from the control group people that do not represent the source population, including people infected with other influenza types or other vaccine-preventable respiratory viruses for which vaccination status is correlated. We investigated these biases by comparing the effectiveness of seasonal 2023/24 influenza vaccination against influenza A and B based on PCR versus rapid test results, excluding controls who tested positive for SARS-CoV-2 or the other type of influenza. By PCR, VE against influenza A was 49% (95%CI 26–65%) after exclusion of PCR-confirmed influenza B and SARS-CoV-2 controls. Corresponding VE against influenza B was 65% (95%CI 35–81%). VE estimated by adjusting for COVID-19 vaccination status yielded similar estimates to the scenario that excluded SARS-CoV-2-positive controls. When case/control status and exclusions from test-negative controls were determined by rapid test, VE was reduced by 5–15 percentage points. Bias correction methods were able to reduce these discrepancies. When estimating VE from a test-negative study using rapid test results, methods to correct misclassification bias are recommended.

  • Open Access

    Comparative effectiveness of monovalent XBB.1.5 containing covid-19 mRNA vaccines in Denmark, Finland, and Sweden: target trial emulation based on registry data

    by Niklas Worm Andersson, Emilia Myrup Thiesson, Nicklas Pihlström, Jori Perälä, Kristýna Faksová, Mie Agermose Gram, Eero Poukka, Tuija Leino, Rickard Ljung, Anders Hviid

    Objective: To estimate the effectiveness of vaccination with a monovalent covid-19 mRNA vaccine containing the omicron XBB.1.5 subvariant against severe covid-19 disease in Denmark, Finland, and Sweden. Design: Target trial emulation based on registry data. Setting: Denmark, Finland, and Sweden, 1 October 2023 to 21 April 2024. Participants: Source population of 3 898 264 individuals eligible for vaccination with the XBB.1.5 containing covid-19 mRNA vaccine at the start of the study on 1 October 2023. Study cohort comprised 1 876 282 recipients of an XBB.1.5 containing vaccine during the study period matched with 1 876 282 non-recipients. Individuals were aged ≥65 years (mean age 75.4 years, standard deviation 7.4 years) and had received at least four doses of a previous covid-19 vaccine. Main outcome measures: Cumulative incidences of hospital admissions and deaths related to covid-19 in a follow-up period of 24 weeks after immunisation (defined as one week after vaccination) in recipients of an XBB.1.5 containing covid-19 mRNA vaccine and matched non-recipients. Cumulative incidences were used to calculate comparative vaccine effectiveness (1−risk ratio) and risk differences. Results: The associated comparative vaccine effectiveness was 57.9% (95% confidence interval (CI) 49.9% to 65.8%) against hospital admission for covid-19 (1085 v 2635 events) and 75.2% (70.6% to 79.9%) against deaths related to covid-19 disease (348 v 1458 events) after 24 weeks of follow-up. This result corresponded to 154.7 (95% CI 78.3 to 231.0) hospital admissions for covid-19 and 120.3 (110.5 to 130.2) deaths prevented per 100 000 individuals who were vaccinated with an XBB.1.5 containing vaccine. The associated comparative vaccine effectiveness was similar irrespective of sex, age group (65-74 v ≥75 years), number of doses of previous covid-19 vaccines, subgroup of co-administered seasonal influenza vaccines, and period of when either the omicron XBB or BA.2.86 sublineage was predominant. Although the observed reduction in risk was highest during the first weeks after vaccination, comparative vaccine effectiveness was well maintained after 24 weeks of follow-up. Conclusions: In this study, in adults aged ≥65 years, vaccination with a monovalent XBB.1.5 containing covid-19 mRNA vaccine was associated with reduced rates of hospital admissions for covid-19 and deaths related to covid-19, during the autumn and winter of 2023-24 in Denmark, Finland, and Sweden.


  • Open Access

    Relative effectiveness of bivalent boosters against severe COVID-19 outcomes among people aged ≥ 65 years in Finland, September 2022 to August 2023

    by Eero Poukka, Jori Perälä, Hanna Nohynek, Sirkka Goebeler, Kari Auranen, Tuija Leino, Ulrike Baum

    Background: Long-term effectiveness data on bivalent COVID-19 boosters are limited. Aim: We evaluated the long-term protection of bivalent boosters against severe COVID-19 among ≥ 65-year-olds in Finland. Methods: In this register-based cohort analysis, we compared the risk of three severe COVID-19 outcomes among ≥ 65-year-olds who received a bivalent booster (Original/Omicron BA.1 or Original/BA.4–5; exposed group) between 1/9/2022 and 31/8/2023 to those who did not (unexposed). We included individuals vaccinated with at least two monovalent COVID-19 vaccine doses before 1/9/2022 and ≥ 3 months ago. The analysis was divided into two periods: 1/9/2022–28/2/2023 (BA.5 and BQ.1.X predominating) and 1/3/2023–31/8/2023 (XBB predominating). The hazards for the outcomes between exposed and unexposed individuals were compared with Cox regression. Results: We included 1,191,871 individuals. From 1/9/2022 to 28/2/2023, bivalent boosters were associated with a reduced risk of hospitalisation due to COVID-19 (hazard ratio (HR): 0.45; 95% confidence interval (CI): 0.37–0.55), death due to COVID-19 (HR: 0.49; 95% CI: 0.38–0.62), and death in which COVID-19 was a contributing factor (HR: 0.40; 95% CI: 0.31–0.51) during 14–60 days since vaccination. From 1/3/2023 to 31/8/2023, bivalent boosters were associated with lower risks of all three severe COVID-19 outcomes during 61–120 days since a bivalent booster (e.g. HR: 0.53; 95% CI: 0.39–0.71 for hospitalisation due to COVID-19); thereafter no notable risk reduction was observed. No difference was found between Original/Omicron BA.1 and Original/BA.4–5 boosters. Conclusion: Bivalent boosters initially reduced the risk of severe COVID-19 outcomes by ca 50% among ≥ 65-year-olds, but protection waned over time. These findings help guide vaccine development and vaccination programmes.


  • Open Access

    Comparative effectiveness of bivalent BA.4–5 or BA.1 mRNA booster vaccines among immunocompromised individuals across three Nordic countries: A nationwide cohort study

    by Mie Agermose Gram, Emilia Myrup Thiesson, Nicklas Pihlström, Jori Perälä, Eero Poukka, Tuija Leino, Rickard Ljung, Niklas Worm Andersson, Anders Hviid


  • Open Access

    Comparative effectiveness of the monovalent XBB.1.5-containing covid-19 mRNA vaccine across three Nordic countries

    by Niklas Worm Andersson, Emilia Myrup Thiesson, Nicklas Pihlström, Jori Perälä, Kristýna Faksová, Mie Agermose Gram, Eero Poukka, Tuija Leino, Rickard Ljung, Anders Hviid

    Objective: To estimate the effectiveness of vaccination with a monovalent XBB.1.5-containing covid-19 mRNA vaccine against severe covid-19 across three Nordic countries. Design: Nationwide cohort studies, using target trial emulation. Setting: Denmark, Finland, and Sweden, from 1 October 2023 to 29 February 2024. Participants: Individuals aged ≥65 years who had previously received at least four covid-19 vaccine doses. Main outcome measures: Cumulative incidences of covid-19 hospital admission and death for 12 weeks after immunisation (defined as 1 week after vaccination) among recipients of an XBB.1.5-containing covid-19 mRNA vaccine and matched non-recipients. Cumulative incidences were used to calculate comparative vaccine effectiveness (1-risk ratio) and risk differences. Results: During autumn and winter 2023-2024, a total of 1,867,448 1:1 matched pairs of XBB-containing covid-19 mRNA vaccine recipients and non-recipients were included (mean age 75.4 years, standard deviation 7.4 years). The comparative vaccine effectiveness was 60.6% (95% confidence interval, 46.1% to 75.1%) against covid-19 hospital admission (930 v 2,551 events) and 77.9% (69.2% to 86.7%) against covid-19 related death (301 v 1,326 events) at 12 weeks of follow-up. This corresponded to 191.1 (95% confidence interval, 50.2 to 332.1) covid-19 hospital admissions and 109.2 (100.2 to 118.1) deaths prevented per 100,000 individuals vaccinated with an XBB.1.5-containing vaccine. The comparative vaccine effectiveness was similar across sex, age (65-74/≥75 years), number of previous covid-19 vaccine doses received, and seasonal influenza vaccination co-administration subgroups and periods of either omicron XBB- or BA.2.86-sublineage dominance. While the protection was highest during the first weeks after vaccination, it was well-preserved at end of week 12 of follow-up. Conclusion: Among adults aged ≥65 years, vaccination with a monovalent XBB.1.5-containing covid-19 mRNA vaccine reduced the rates of covid-19 related hospital admission and death during autumn and winter 2023-2024 across three Nordic countries.


  • Open Access

    Comparative effectiveness of bivalent BA.4.5 or BA.1 mRNA booster vaccines among immunocompromised individuals across three Nordic countries: a nationwide cohort study

    by Mie Agermose Gram, Emilia Myrup Thiesson, Nicklas Pihlström, Jori Perälä, Eero Poukka, Tuija Leino, Rickard Ljung, Niklas Worm Andersson, Anders Hviid

    Objectives To estimate the effectiveness and waning immunity of the bivalent BA.4-5 or BA.1 mRNA booster vaccine against Covid-19-related hospital admission and death in immunocompromised individuals. Design Nationwide cohort analyses using a matched cohort design. Setting Denmark, Finland, and Sweden, from 1 September 2022 to 31 October 2023. Participants All individuals aged 18 years or above with medical history of at least one immunocompromised condition, residency in Denmark, Finland or Sweden, no history of Covid-19-related hospitalization, and receipt of at least three Covid-19 vaccine doses as of study start, 1 September 2022. Individuals boosted with a BA.4-5 or BA.1 vaccine were matched 1:1 with unboosted individuals. Main outcome measures Country-combined vaccine effectiveness (VE) estimates against Covid-19 hospitalization and Covid-19- related death at day 270 of follow-up. Potential waning was assessed in 45-day intervals. Results A total of 352,762 BA.4-5 and 191,070 BA.1 booster vaccine doses were administered to immunocompromised individuals. At day 270, the comparative VE against Covid-19 hospitalization was 34.2% (95% CI, 7.1% to 61.3%) for the bivalent BA.4-5 vaccine (696 vs 1,128 events, risk difference [RD] per 100,000, -223.7, 95% CI, -411.5 to -36.0) and 42.6% (95% CI, 31.3% to 53.9%) for the BA.1 vaccine (395 vs 740 events, RD per 100,000, -385.0, -673.4 to -96.6) compared with matched unboosted. The comparative VE against Covid-19 death was 53.9% (95% CI, 38.6% to 69.3%) for the bivalent BA.4-5 vaccine (203 vs 457 events, RD per 100,000, -138.7, 95% CI, -195.5 to -81.9) and 57.9% (95% CI, 48.5% to 67.4%) for the BA.1 vaccine (112 vs 302 events, RD per 100,000, -220.6, -275.9 to -165.4). The VE estimates were highest in the first 45 days since eight days after vaccination (52.8% and 72.8% for bivalent BA.4-5 vaccine against Covid-19-related hospitalization and death, and 62.2% and 84.2% for bivalent BA.1 vaccine) and waned gradually during the 270 days of follow-up. Conclusions In immunocompromised individuals, vaccination with a bivalent BA.4-5 or BA.1 booster lowered the risk of Covid-19-related hospitalization and death over a follow-up period of 9 months. The effectiveness was highest during the first months since vaccination with subsequent gradual waning. What is already known on this topic Bivalent BA.4-5 or BA.1 booster vaccination increases protection against severe Covid-19 outcomes in the general population. Lower effectiveness of the original monovalent Covid-19 vaccines among immunocompromised individuals has been observed relative to the effectiveness within the general population. What this study adds Bivalent BA.4-5 or BA.1 booster vaccination increased the protection against Covid-19 outcomes among immunocompromised individuals. At day 270 of follow-up, the bivalent BA.4-5 booster had prevented 223.7 hospitalizations and 138.7 deaths related to Covid-19 per 100,000 boosted individuals. For the bivalent BA.1 booster, corresponding numbers were 385.0 and 220.6, respectively. The vaccine effectiveness was highest during the first 45 days since eight days after vaccination (52.8% and 72.8% for bivalent BA.4-5 vaccine against Covid-19-related hospitalization and death, and 62.2% and 84.2% for bivalent BA.1 vaccine) and waned gradually during the 270 days of follow-up.